Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 1026 results for "novartis"

Novartis AG Rating Reiterated by Zacks (NVS)

Novartis AG (NYSE:NVS) Several other analysts have also recently commented on the stock. Analysts at Barclays upgraded shares of Novartis AG from an "underweight" rating to an "equal weight" rating in a research note on Monday, June 9th. American Banking News, 30 minutes ago
Why Novartis (NVS) Stock Is Down Today, 1 week ago

1,382 images for novartis

MSN India, 10 hours ago
Orlando Sentinel, 1 day ago
BioSpace, 3 hours ago
Yahoo! News, 1 day ago
Reuters India, 1 day ago
Sify, 4 days ago
Deutsche Welle, 1 day ago
TopNews United States, 1 week ago
Bidness Etc, 1 week ago, 1 week ago

Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Summary: Novartis' second quarter results were disappointing. Core earnings per share came in at $1.34, up 7% from the year-ago period but missed the Zacks Consensus Estimate of $1.36. Revenues increased 2% year over year to $14.6 billion but ...
 Zacks.com33 minutes ago Novartis Misses on Q2 Earnings & Revenue, Outlook Retained  Yahoo! Finance1 week ago Novartis had modest Q2 sales gain  MedNous1 week ago Roche's 1H14 Earnings & Revenues Up Y/Y, Outlook Reaffirmed  Yahoo! Finance5 hours ago
MSN India

Novartis India reports marginal rise in Q1 net

Reeling under the impact of the reduction in prices of its medicines due to the expanded control of the Drug Price Control Order (DPCO), Novartis India reported a marginal 3.17 per cent rise in its standalone net profit to Rs 14.31 crore for the ...
 The Hindu6 hours ago Novartis India Q1 net up 3 pc at Rs 14.31 cr  Business Standard12 hours ago Novartis India Q1 profit rises to Rs 14.3 cr  Money Control12 hours ago Novartis India net sales plunge by 8% in Q1  PharmaBiz12 hours ago
Reuters India

Novartis To Offer Stiff Competition To Amgen's Neupogen

at 6:20 am EST Click Ticker to See live coverage Novartis AG (ADR) ( NVS ) announced yesterday that the Food and Drug Administration (FDA) had accepted the Biologics License Application for filgrastim by Sandoz the generics arm of ...
 Bidness Etc10 hours ago US FDA accepts Sandoz biologics license application for filgrastim  PharmaBiz15 hours ago FDA Accepts First Biosimilar Filing  PharmTech.com22 hours ago FDA accepts BLA for biosimilar of Amgen's Neupogen  Seeking Alpha1 day ago
Yahoo! Finance

Novartis India net profit rises 3.17% in the June 2014 quarter

Presents In Partnership with Live Streaming Partner Trading Partner
 Business Standard11 hours ago Google partners with Novartis  Healthcare Today11 hours ago 07.22.14 -- Google Picks Novartis To Co-Develop 'Smart Lens'; Cutting Through The Remote Patient Monitoring Hype  Medical Design Online3 days ago Novartis throws weight behind Google's smart contact lens  Business Recorder4 days ago

Novartis Biotechnology Leadership Camp selects three women

They will represent India at International BioCamp in Basle, Switzerland Three women, Satarupa Barma and Aditi Ramnath from the Indian School of Business (ISB), Hyderabad and Nidhi Hans pursuing a PhD at the International Centre for Genetic ...
 Express Pharma7 hours ago Women students take top slots at Novartis BioCamp  Hindu Business Line13 hours ago Next edition of Novartis BioCamp to be held in July  Business Line2 months ago

Novartis India: Outcome of AGM

Novartis India has informed that the Annual General Meeting (AGM) of the Company was held on July 25, 2014.
 Money Control9 hours ago Novartis India's AGM on July 25, 2014  Money Control3 weeks ago Novartis India fixes book closure for dividend AGM  Money Control2 months ago

Novartis AG (NVS) Trading Near $89.49 Resistance Level

Novartis AG ("NVS) presents a trading opportunity that offers a 3.28% return in just 177 days. A covered call on Novartis AG at the $87.50 level expiring on Jan. '15 offers an assigned return rate ...
 Individual.com1 day ago Novartis AG (NVS) Showing Support Near $88.07  Individual.com4 days ago Novartis AG (NVS) Showing Bearish Technicals With Support At $88.72  Individual.com2 days ago

Sunitinib or Everolimus First-Line for Kidney Cancer?

Everolimus ( Afinitor , Novartis) is not as effective as sunitinib ( Sutent , Pfizer) in the first-line setting for patients with metastatic renal cell carcinoma, and it has a different toxicity profile, according to a phase2 randomized direct ...
 Medscape1 day ago
Motley Fool

5 Novartis Drugs You Need To Know About

Novartis ( NYSE: NVS ) is one of the planet's top drug manufacturers and its 3% dividend yield makes it a staple in dividend investor portfolios. However, Novartis is facing significant threats from competitors Biogen Idec ( NASDAQ: BIIB ) ...
 Motley Fool2 days ago Novartis Has Returned 15.3% Since SmarTrend Recommendation (NVS)  Individual.com2 days ago Report: Development IT hit hard in Novartis cutbacks  Fierce Biotech IT6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less